论文部分内容阅读
糖尿病性脑梗死患者共86例,随机分为治疗组、对照组各43例。治疗组给予尼麦角林注射液8mg加入生理盐水250ml静脉滴注,每日1次,疗程20天;对照组给予维脑路通注射液400mg。结果:治疗组总有效率显著优于对照组(P<0·01);神经功能缺损和日常生活能力评分优于治疗前(P<0·01)和对照组(P<0·05);全血和血浆粘度、红细胞刚性指数、红细胞聚集指数和血浆比粘度的变化也优于治疗前(P<0·01)及对照组(P<0·05)。结论:尼麦角林治疗糖尿病性脑梗死安全有效。
A total of 86 patients with diabetic cerebral infarction were randomly divided into treatment group and control group, 43 cases each. The treatment group was given nicergoline injection 8mg intravenous infusion of normal saline 250ml, day 1, treatment for 20 days; control group given Venoruton injection 400mg. Results: The total effective rate of the treatment group was significantly better than that of the control group (P <0.01). The score of neurological deficit and daily living ability was better than that before treatment (P <0.01) and control group (P <0.05). Changes of whole blood and plasma viscosity, erythrocyte rigidity index, erythrocyte aggregation index and plasma specific viscosity were also better than before treatment (P <0.01) and control group (P <0.05). Conclusion: Nicergoline is safe and effective for the treatment of diabetic cerebral infarction.